Cargando…

Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4

BACKGROUND: Antibodies and derivative drugs targeting immune checkpoints have been approved for the treatment of several malignancies, but there are fewer responses in patients with pancreatic cancer. Here, we designed a nanobody molecule with bi-targeting on PD-L1 and CXCR4, as both targets are ove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hao, Shuai, Xu, Shuyi, Li, Liangzhu, Li, Yaxian, Zhao, Meiqi, Chen, Junsheng, Zhu, Shunying, Xie, Yueqing, Jiang, Hua, Zhu, Jianwei, Wu, Mingyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594910/ https://www.ncbi.nlm.nih.gov/pubmed/36284271 http://dx.doi.org/10.1186/s12885-022-10165-7

Ejemplares similares

Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system
por: Han, Lei, et al.
Publicado: (2017)

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
por: Chen, Jie, et al.
Publicado: (2023)

Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins
por: Misson Mindrebo, Laetitia, et al.
Publicado: (2023)

Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma
por: Ma, Linlin, et al.
Publicado: (2022)

Design of nanobody-based bispecific constructs by in silico affinity maturation and umbrella sampling simulations
por: Bai, Zixuan, et al.
Publicado: (2022)

A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer
por: Chen, Jie, et al.
Publicado: (2021)

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
por: Xia, Baijin, et al.
Publicado: (2023)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency
por: Fu, Wenyan, et al.
Publicado: (2023)

Monitoring Allosteric Interactions with CXCR4 Using NanoBiT Conjugated Nanobodies
por: Soave, Mark, et al.
Publicado: (2020)

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
por: Chu, Wendi, et al.
Publicado: (2022)

Screening and identification of an anti-PD-1 nanobody with antitumor activity
por: Zhang, Yanting, et al.
Publicado: (2023)

Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates
por: Wakileh, Gamal A., et al.
Publicado: (2023)

Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment
por: Wang, Rongjuan, et al.
Publicado: (2023)

Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement
por: Pan, Zhidi, et al.
Publicado: (2022)

A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
por: Hanke, Leo, et al.
Publicado: (2022)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
por: Liu, Yanlong, et al.
Publicado: (2022)

Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
por: Yang, Xiao-mei, et al.
Publicado: (2023)

A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
por: Zhou, Yuexian, et al.
Publicado: (2020)

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)

Mapping inhibitory sites on the RNA polymerase of the 1918 pandemic influenza virus using nanobodies
por: Keown, Jeremy R., et al.
Publicado: (2022)

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration
por: Wu, Xilin, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid
por: Eigenmann, Miro Julian, et al.
Publicado: (2021)

Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4(+) GBM cells: A proof of principle
por: Sanchez Gil, Judit, et al.
Publicado: (2022)

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
por: Hambach, Julia, et al.
Publicado: (2022)

Research progress and applications of nanobody in human infectious diseases
por: Mei, Yaxian, et al.
Publicado: (2022)

PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations
por: Sun, Xin, et al.
Publicado: (2018)

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization
por: Yang, Jing, et al.
Publicado: (2023)

Novel Lentivirus-Based Method for Rapid Selection of Inhibitory Nanobody against PRRSV
por: Liu, Ze-Hui, et al.
Publicado: (2020)

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
por: Cui, Xiaopei, et al.
Publicado: (2021)

CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients
por: D’Alterio, Crescenzo, et al.
Publicado: (2022)

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
por: Zhong, Zhenwei, et al.
Publicado: (2022)

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
por: Mu, Songlin, et al.
Publicado: (2022)

RPL21 siRNA Blocks Proliferation in Pancreatic Cancer Cells by Inhibiting DNA Replication and Inducing G1 Arrest and Apoptosis
por: Li, Chaodong, et al.
Publicado: (2020)

Recombinant expression of nanobodies and nanobody-derived immunoreagents
por: de Marco, Ario
Publicado: (2020)

A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
por: Sun, Rui, et al.
Publicado: (2021)

Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody
por: Zeronian, Matthieu R., et al.
Publicado: (2022)

Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library
por: Yan, Junrong, et al.
Publicado: (2015)

Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy
por: Zhu, Lipeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6nrouqbqcj6pkdj0fvi4b2dlag